A well-designed pharmaceutical intermediate often combines several functional features in one molecular structure. 2-(2-Fluoro-4-iodoanilino)-3,4-difluorobenzoic acid (CAS 391211-97-5) is an example: it contains a fluorinated diarylamine framework, an iodine substituent, and a carboxylic acid group.
These features make it a useful advanced building block in the synthesis of Mirdametinib (PD-0325901), a selective MEK1/2 inhibitor.
Product Identity and Molecular Specifications
The compound consists of two aromatic rings connected through an anilino linkage. Three fluorine atoms, one iodine atom, and a carboxylic acid group contribute to its chemical properties and synthetic usefulness.
- · Product Name: 2-(2-Fluoro-4-iodoanilino)-3,4-difluorobenzoic acid
- · CAS Number: 391211-97-5
- · Molecular Formula: C₁₃H₇F₃INO₂
- · Molecular Weight: 393.10 g/mol
- · Synonyms: 3,4-Difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid; 3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzoic acid
- · Typical Purity: 98% as listed in the supplied product specification
PubChem, the FDA Substance Registration System, and independent supplier records confirm the chemical identity and molecular data.
Three Functional Features in One Intermediate
The value of this molecule can be understood through its three main structural elements.
1. Fluorinated aromatic framework
The fluorine substituents influence the electronic properties of the aromatic rings. Fluorinated aromatic structures are common in medicinal chemistry because they provide opportunities to adjust molecular polarity, lipophilicity, and metabolic behavior.
2. Diarylamine linkage
The anilino connection joins the two aromatic fragments and establishes an important part of the final Mirdametinib framework.
3. Carboxylic acid functionality
The carboxylic acid serves as the coupling site for introducing the hydroxylamine-derived side chain.
Together, these features make the compound more than a simple fluorinated benzoic acid. It is an advanced aromatic building block designed for further molecular assembly.
How It Participates in Mirdametinib Synthesis
The relationship between this intermediate and Mirdametinib is supported by published synthesis information.
In a reported route, 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid is coupled with the chiral hydroxylamine derivative CAS 114778-50-6. Carbonyldiimidazole is used to facilitate formation of the corresponding protected benzamide intermediate. Subsequent deprotection provides the dihydroxypropoxy side chain present in Mirdametinib.
This route illustrates the complementary roles of the two intermediates:
- · CAS 391211-97-5 supplies the fluorinated diarylamine benzoic acid framework.
- · CAS 114778-50-6 supplies the chiral protected hydroxylamine side chain.
Their controlled combination produces a substantially more complex pharmaceutical structure.
Why the Iodine Substituent Is Important
The iodine substituent is a distinctive feature of this compound.
In organic synthesis, aryl iodides can serve as useful functional handles for selected cross-coupling and other transformation strategies. The suitability of these reactions depends on the substrate and process design.
In this particular Mirdametinib route, however, the reported coupling step uses the carboxylic acid functionality to attach the hydroxylamine-derived side chain. The iodine substituent remains part of the resulting molecular structure.
This distinction is important: buyers should understand the actual role of each functional group rather than assume that every halogen substituent must be used in a coupling reaction.
Quality Requirements for Advanced Aromatic Intermediates
The compound’s multiple halogen substituents and advanced structure make analytical control important.
Key procurement considerations include:
- · Confirmation of the correct CAS number and molecular structure
- · HPLC purity and related-substance profile
- · Identity confirmation by mass spectrometry and NMR
- · Residual starting materials and process impurities
- · Water content and storage stability
- · Batch-to-batch consistency
The iodine-containing structure makes it especially important to distinguish the desired compound from closely related halogenated aromatic impurities.
SHLZ Pharma: Technical Development and Supply
Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. provides pharmaceutical intermediate development, customization, and production services.
Its official profile describes a 1,000-square-meter R&D laboratory, two pilot workshops, and process equipment supporting reactions from ultra-low to high temperatures. The company also reports laboratory customization from grams to kilograms and larger-scale pilot and factory production.
For customers sourcing advanced Mirdametinib intermediates, these capabilities can support discussions involving analytical standards, process optimization, and scale-up requirements.
Conclusion
2-(2-Fluoro-4-iodoanilino)-3,4-difluorobenzoic acid (CAS 391211-97-5) is an advanced fluorinated aromatic building block used in a published Mirdametinib synthesis route.
Its molecular formula is C₁₃H₇F₃INO₂, and its molecular weight is 393.10 g/mol. The combination of a diarylamine framework, fluorine substituents, iodine, and a carboxylic acid group gives it a clearly defined role in pharmaceutical intermediate chemistry.
For procurement, identity, assay, impurity profile, and batch consistency should be assessed together.
Post time: Nov-13-2026
